Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23248501 | 0.87 | POLB (0.45) | SMN1; SMN2LMNAALDH1A1MAPTKMT2A | |
| SCHEMBL15882234 | 0.79 | VCAM1 (0.39) | SMN1; SMN2PKMLMNAALDH1A1MAPT | |
| SCHEMBL38653331 | 0.77 | PIN1 (0.46) | PKMALDH1A1GAAVCAM1 | |
| SCHEMBL2523142 | 0.77 | NPBWR1 (0.35) | SMN1; SMN2PKMKMT2A | |
| SCHEMBL2521727 | 0.76 | MEN1 (0.48) | PKMKMT2AMEN1HPGDGAA | |
| SCHEMBL28312825 | 0.75 | LMNA (0.42) | SMN1; SMN2PKMLMNAALDH1A1MAPT | |
| SCHEMBL28534811 | 0.75 | SMN1; SMN2 (0.64) | SMN1; SMN2PKMLMNAALDH1A1MAPT | |
| SCHEMBL15882288 | 0.75 | SMN1; SMN2 (0.34) | SMN1; SMN2PKMLMNAALDH1A1MAPT | |
| SCHEMBL14801244 | 0.75 | NPBWR1 (0.53) | SMN1; SMN2MAPT | |
| SCHEMBL19432663 | 0.75 | PKM (0.33) | SMN1; SMN2PKMLMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358879-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-15 | — | — | US | disclosed |
| EP-4046688-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-4046688-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021075476-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 | 2021-04-22 | — | — | WO | disclosed |
| EP-2900657-B1 | CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-03-11 | — | — | EP | disclosed |
| EP-3119775-B1 | OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2019-11-06 | — | — | EP | disclosed |
| EP-3119775-B1 | OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2019-11-06 | — | — | EP | disclosed |
| US-9963446-B2 | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963446-B2 | Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-8436001-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-07 | — | — | US | disclosed |
| WO-2013045461-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013045461-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2556066-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011124580-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | SMN1; SMN2 2907/4885PKM 12/4885LMNA 755/4885 |
| US-20230322683-A1 | HETEROCYCLIC COMPOUND | PARK7, SMN1; SMN2, SNCA | SMN1; SMN2 2/4885PKM 615/4885LMNA 420/4885 |
| US-12358879-B2 | Heterocyclic compound | PARK7, SMN1; SMN2, SNCA | SMN1; SMN2 2/4885PKM 615/4885LMNA 420/4885 |
| US-20130079321-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | SMN1; SMN2 2578/4885PKM 8/4885LMNA 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.